Overexpression of the epidermal growth factor receptor (EGFR) is a hallmark of head and neck cancers and confers increased resistance and inferior survival rates. Despite targeted agents against EGFR, such as cetuximab (C225), almost half of treated patients fail this therapy, necessitating novel therapeutic strategies. Poly (ADP-Ribose) polymerase (PARP) inhibitors (PARPi) have gained recent attention due to their unique selectivity in killing tumors with defective DNA repair. In this study, we demonstrate that C225 enhances cytotoxicity with the PARPi ABT-888 in UM-SCC1, UM-SCC6, and FaDu head and neck cancer cells. The mechanism of increased susceptibility to C225 and PARPi involves C225-mediated reduction of non-homologous end-joining (NHEJ)- and homologous recombination (HR)-mediated DNA double strand break (DSB) repair, the subsequent persistence of DNA damage, and activation of the intrinsic apoptotic pathway. By generating a DSB repair deficiency, C225 can render head and neck tumor cells susceptible to PARP inhibition. The combination of C225 and the PARPi ABT-888 can thus be an innovative treatment strategy to potentially improve outcomes in head and neck cancer patients. Furthermore, this strategy may also be feasible for other EGFR overexpressing tumors, including lung and brain cancers.
References
[1]
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology 8: 1197–1206.
[2]
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.
[3]
Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170–4176.
[4]
Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166–2174.
[5]
Rodemann HP, Dittmann K, Toulany M (2007) Radiation-induced EGFR-signaling and control of DNA-damage repair. International Journal of Radiation Biology 83: 781–791.
[6]
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, et al. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350–7356.
[7]
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 11: 21–28.
[8]
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917–921.
[9]
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123–134.
[10]
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences 105: 17079–17084.
[11]
Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, et al. (2007) ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models. Clinical Cancer Research 13: 2728–2737.
[12]
Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, et al. (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65: 3328–3335.
[13]
Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, et al. (2005) Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase. J Biol Chem 280: 31182–31189.
[14]
Li L, Wang H, Yang ES, Arteaga CL, Xia F (2008) Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 68: 9141–9146.
[15]
Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, et al. (2010) AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs.
[16]
Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, et al. (1999) Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14: 451–463.
[17]
Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, et al. (2000) Enhanced Apoptosis With Combination C225/Radiation Treatment Serves as the Impetus for Clinical Investigation in Head and Neck Cancers. Journal of Clinical Oncology 18: 47–53.
[18]
Baker SR (1985) An in vivo model for squamous cell carcinoma of the head and neck. Laryngoscope 95: 43–56.
[19]
Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, et al. (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head & Neck 32: 417–426.
[20]
Rangan SR (1972) A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29: 117–121.
[21]
Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, et al. (2009) Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. Journal of Clinical Oncology 27: 2705–2711.
[22]
Niu G, Sun X, Cao Q, Courter D, Koong A, et al. (2010) Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 16: 2095–2105.
Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071–1078.
[25]
Bryant HE, Helleday T (2006) Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Research 34: 1685–1691.
[26]
Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R (1998) Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells. Journal of Biological Chemistry 273: 1568–1573.
[27]
Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Kehlbach R, et al. (2010) Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett 584: 3878–3884.
[28]
Chan DW, Chen BP, Prithivirajsingh S, Kurimasa A, Story MD, et al. (2002) Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 16: 2333–2338.
[29]
Lieber MR, Ma Y, Pannicke U, Schwarz K (2003) Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 4: 712–720.
[30]
Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) [gamma]H2AX and cancer. Nat Rev Cancer 8: 957–967.
[31]
Zhang Y, Wang J, Liu F, You Z, Yang R, et al. (2010) EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells. Cancer Cell International 10: 39.
[32]
Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, et al. (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838–4848.
[33]
Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, et al. (2010) Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 70: 6277–6282.
[34]
Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, et al. (2009) A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Research 11: R78.
[35]
Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, et al. (2009) Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8: 730–738.
[36]
Albert JM, Cao C, Kim KW, Willey CD, Geng L, et al. (2007) Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models. Clinical Cancer Research 13: 3033–3042.
[37]
Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, et al. (2010) Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings of the National Academy of Sciences 107: 2201–2206.
[38]
Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, et al. (2007) Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys 69: S109–111.
[39]
Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, et al. (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24: 841–849.
[40]
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, et al. (2010) Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. New England Journal of Medicine 363: 24–35.
[41]
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, et al. (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261–269.
[42]
Pang E, Delic NC, Hong A, Zhang M, Rose BR, et al. (2010) Radiosensitization of Oropharyngeal Squamous Cell Carcinoma Cells by Human Papillomavirus 16 Oncoprotein E6 *I. Int J Radiat Oncol Biol Phys.
[43]
Wang H, Yang ES, Jiang J, Nowsheen S, Xia F (2010) DNA Damage Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation. Cancer Research 70: 6258–6267.
[44]
Yang ES, Wang H, Jiang G, Nowsheen S, Fu A, et al. (2009) Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest 119: 1124–1135.
[45]
Feng Z, Kachnic L, Zhang J, Powell SN, Xia F (2004) DNA Damage Induces p53-dependent BRCA1 Nuclear Export. Journal of Biological Chemistry 279: 28574–28584.
